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Abstract
Background Prostate cancer is an important public health
problem. It is an excellent candidate disease for chemo-
prevention because prostate cancer is typically slow
growing and is usually diagnosed in elderly males. Pygeum
africanum (Prunus africana or Rosaceae) is an African
prune (plum) tree found in tropical Africa. An extract from
the bark of Pygeum africanum has been used in Europe as a
prevention and treatment of prostate disorders including
benign prostatic hypertrophy (BPH). More recently in the
USA, the phytotherapeutic preparations of Pygeum afri-
canum and Saw palmetto have been marketed for prostate
health including prostate cancer prevention and treatment.
Methods The anti-cancer potential of Pygeum africanum
has been tested both in vitro (PC-3 and LNCaP cells) and
in vivo (TRAMP mouse model).
Results In tissue culture, ethanolic extracts (30%) of
Pygeum africanum inhibited the growth of PC-3 and
LNCaP cells; induced apoptosis and altered cell kinetics;
down regulated ERa and PKC-a protein, and demonstrated
good binding ability to both mouse uterine estrogen
receptors and LNCaP human androgen receptors. TRAMP
mice fed Pygeum africanum showed a significant reduction
(P = 0.034) in prostate cancer incidence (35%) compared
to casein fed mice (62.5%).
Conclusion Pygeum africanum, which is widely used in
Europe and USA for treatment of BPH, has a significant
role in regulation of prostate cancer both in vitro and
in vivo and therefore may be a useful supplement for
people at high risk for developing prostate cancer.
Keywords African herb  LNCaP  PC-3  TRAMP mice
Introduction
Prostate cancer is an important public health problem
accounting for more than 232,000 new cases and 33,000
deaths in the USA in 2006 [1]. Prostate cancer is an
excellent candidate disease for chemo-prevention because
it is typically slow growing and is usually diagnosed in
elderly males, therefore even a modest delay in the neo-
plastic development achieved through pharmacological or
nutritional intervention could result in a substantial
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reduction in the incidence of mortality [2]. The incidence
of prostate cancer is lower in Asian populations and in
vegetarians compared to populations consuming a more
Western diet [3].
Components of the Western diet, most often cited as
playing a role in increased prostate cancer risk are animal
products [4]. The most consistent correlation for prostate
cancer prevention is consumption of fruits, vegetables, and
grains, which are potential sources of phytoestrogens [5].
Phytoestrogens are found in many plants which are com-
monly used in traditional medicine. Phytoestrogens may
be either agonists or antagonists of estrogen receptors.
Therefore, it has been proposed that phytoestrogens may
influence prostate cancer cell growth and therefore herbal
therapies have been developed which include these com-
pounds [6]. In vivo and in vitro studies have shown that
phytoestrogens may influence not only steroid hormone
metabolism and biological activity, but also intracellular
enzymes, growth factor action, protein synthesis, malignant
cell proliferation, and angiogenesis, thus making them
strong candidates for anticarcinogenic agents [7].
Pygeum africanum (Prunus africana or Rosaceae) is an
African prune (plum) tree found in tropical Africa [8]. The
bark has been used in Europe since 1969 as a prevention
and treatment of prostate disorders including benign pros-
tatic hypertrophy (BPH). Also in Asia, and Africa, phyto-
therapy is considered a first line treatment for prostate
disorders and has been utilized effectively for centuries. In
the USA, phytotherapeutic preparations containing Pygeum
africanum and Saw palmetto are increasingly being mar-
keted for the health of the prostate including prostate
cancer prevention and treatment [9, 10]. Phytochemical
investigations aimed at isolating the active ingredients of
Pygeum africanum have identified many compounds
including fatty acids, sterols (B-Sitosterol and Campester-
ol) and pentacyclic triterpenoids [11]. Multicenter clinical
trials have been done to study the role of Pygeum africa-
num in prevention and treatment of BPH [12–22]; however
one study on the mechanism of action of Pygeum africa-
num in prostate cancer has been described [23]. The major
effects of Pygeum africanum have been reported to be
caused by its main active ingredient, B-Sitosterol which is
present in high concentrations in the Pygeum africanum
extract [24, 25].
B-Sitosterol, a sterol related to cholesterol, is present in
three commonly used prostate herbal supplements, Pyge-
um africanum, Saw palmetto, and Hypoxis. These three
herbs are commonly used in commercial supplements for
prostate health [26]. Epidemiological and experimental
studies [2] suggest that dietary phytosterols may offer
protection from the most common cancers in Western
societies, such as colon, breast and prostate cancer. It has
been proposed that phytosterols such as B-Sitosterol
affect membrane structure and function of tumor and host
tissues, signal transduction pathways that regulate tumor
growth and apoptosis [27]. The role of B-Sitosterol in
prevention and treatment of BPH has been studied both in
tissue culture and in clinical trials [28–30] however there
are few studies on the role of B-Sitosterol in prostate
cancer. Von Holtz et al. [31] reported that B-Sitosterol
inhibited the growth of LNCaP cells and induced apop-
tosis via activation of the sphingomyelin cycle. Also
Awad et al. [32, 33] found B-Sitosterol inhibited the
growth and dissemination of PC-3 cells both in vitro and
in vivo.
The aim of this work was to explore the possible
mechanisms by which Pygeum africanum regulates pros-
tate cancer both in vitro (LNCaP and PC-3 human prostate
cancer cell lines) and in vivo (in TRAMP Prostate Cancer
Mouse model). These cell lines were selected to provide an
androgen sensitive (LNCaP) and an androgen insensitive
(PC-3) comparison. To our knowledge, this is the first
report that extensively describes the anti-prostate cancer
activity of Pygeum africanum both in vitro and in vivo.
Results
In vitro experiments
Pygeum africanum extract inhibited the growth of both
PC-3 and LNCaP cells (Fig. 1). The IC50 (the concentra-
tion of the compound that is required to inhibit cell growth
by 50%) was approximately 2.5 ll/ml (for both cell lines).
B-Sitosterol inhibited the growth of LNCaP cells but had
no effect on the growth of PC-3 cells (Fig. 2).
Cell proliferation was measured using a thymidine
incorporation assay in the two prostate cancer cell lines
over 3 days incubated with and without the 2.5 ll/ml of
Pygeum africanum. In PC-3 and LNCaP cells, Pygeum
africanum inhibited growth by 50% from day 1 through
day 3 (Fig. 3).
In both prostate cancer cell lines, a significant increase
in the number of cells in the S phase of the cell cycle was
induced by Pygeum africanum in PC-3 (Fig. 4B) and
LNCaP (Fig. 4D) cells when compared to untreated cells
(Fig. 4 A, C).
Pygeum africanum at 2.5 ll/ml induced significant
apoptosis in both cell lines (PC-3 and LNCaP) when
compared with untreated cells (Table 1).
Pygeum africanum and B-Sitosterol were tested for their
potential to displace bound estradiol in mouse uterine
cytosol using the competitive 3H-estradiol ligand-binding
assay. At 5 ll/ml Pygeum africanum displaced >70% of
3H-estradiol; however, B-Sitosterol (5 lM) did not com-
pete for 3H-estradiol binding (Fig. 5).
Endocr (2007) 31:72–81 73
Pygeum africanum and B-Sitosterol were tested for their
potential to displace bound DHT in LNCaP cell cytosol
using the competitive 3H-DHT ligand-binding assay. At
5 ll/ml Pygeum africanum displaced >60% of 3H-DHT;
however, B-Sitosterol (5 lM) was not able to compete for
3H-DHT binding (Fig. 6).
Pygeum africanum showed a dose dependent inhibition
of ERa protein expression in PC-3 cells (Fig. 7). Also
Pygeum africanum at 2.5 ll/ml inhibited PKC-a expres-
sion in LNCaP but not in PC-3 cells (Fig. 8).
In vivo experiments
Among TRAMP mice fed Pygeum africanum extract for
5 months, fewer animals developed prostate cancer (35%)
than mice fed the casein diet (62.5%). The largest effect
was on WDC incidence (P = 0.034; Table 2). There was a
non-significant effect on PDC ‘‘neuro-endocrine like car-
cinoma incidence’’ (P = 0.78).
There was no significant effect of diet on total body
weight, reproductive tract, testes or prostate weights
(Table 3). The large variation in the prostate weight in the
in vivo treatment group was because one of the tumors in
PDC stage of the Pygeum africanum fed group was huge.
The difference in PDC incidence was still not statistically
significant (P > 0.05).
Discussion
In the present study, an extract of Pygeum africanum in-
duced 50% growth inhibition of both PC-3 and LNCaP
cells. This was in agreement with Margalef et al. [8] who
reported growth inhibition of prostate cancer-derived cells
(LNCaP and CA-HPV-10). The inhibition of the growth
of PC-3 and LNCaP cells was present from day 1 through
day 3 of incubation with the Pygeum africanum extract.
The effect of Pygeum on the prostate cancer cell lines was
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Fig. 1 PC-3 (A) and LNCaP (B) cells were plated at 1 · 104 cells per
well in 24 well dishes and grown to 50% confluence. After 2 days the
media was replaced with complete media containing 0–10 ll/ml of
Pygeum africanum (30% ethanol extract) and incubated for 72 h. The
total cellular protein concentration was determined by DC Bio-Rad
assay. The IC50 for Pygeum africanum was calculated based on the
growth inhibition after 72 h in comparison to the zero treatment
control. Values are means ± SEM of three individual experiments
(Each individual experiment was performed in duplicate)
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Fig. 2 PC-3 (A) and LNCaP (B) cells were plated at 1 · 104 cells per
well in 24 well dishes and grown to 50% confluence. After 2 days
the media was replaced with complete media containing 0–25 lM B-
sitosterol loaded on cyclodextrin (CD) and incubated for 72 h. The
total cellular protein concentration was determined by DC Bio-Rad
assay. The IC50 for B-sitosterol was calculated based on the growth
inhibition after 72 h in comparison to the zero treatment control.
Values are means ± SEM of three individual experiments (Each
individual experiment was performed in duplicate)
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not a toxic effect as we saw no effect of Pygeum africanum
on the CaCO2 (Colon Cancer) cell line that has similar
metabolic activity and cell cycle time, at concentrations up
to 20 ll/ml of the ethanolic extract of Pygeum africanum
(Data not shown).
Phytochemical investigations aimed at isolating the ac-
tive ingredients of Pygeum africanum have been exten-
sively undertaken. Many compounds have been identified
including fatty acids, sterols (B-Sitosterol and Campester-
ol) and pentcyclic triterpenoids [11]. B-Sitosterol, as one of
the marker compounds for Pygeum africanum, has been
tested for its ability to inhibit the growth of both PC-3 and
LNCaP cells [32, 33]. Few studies on the role of B-Sitos-
terol in prostate cancer have been described. We found that
B-Sitosterol inhibited the growth of LNCaP cells. This
agrees with Von Holtz et al. [31] who reported that B-
Sitosterol inhibited the growth of LNCaP cells and induced
apoptosis via activation of the sphingomyelin cycle or by
regulation of the activity of PKC-alpha [34]. Also Awad
et al. [27] reported that B-Sitosterol might affect mem-
brane structure and function of tumor and host tissues,
signal transduction pathways that regulate tumor growth,
and apoptosis However, we found no effect of B-Sitosterol
on PC-3 cell growth but we did see an effect similar to
Awad et al. [32] who showed that B-sitosterol inhibited the
growth of LNCaP cells in vitro. However, in contrast to our
results Awad et al. found an effect of B-Sitosterol on PC-3
cell growth in 5% non-stripped serum [33].
The present study showed that Pygeum africanum at
2.5 ll/ml induced an accumulation of the cells in the S
phase of the cell cycle for both PC-3 and LNCaP cells, as
well as significant apoptosis compared to untreated cells.
These results differed from Margalef et al. [18] who re-
ported a block in the transition from G1 to S phase in the
cell cycle of PZ-HPV7 cells with an ethanolic extract of
Pygeum africanum.
Interest in the physiological roles of bioactive com-
pounds present in plants has increased dramatically over
the last decade. Of particular interest because of their re-
ported roles in human health is the class of compounds
known as phytoestrogens. Phytoestrogens embody several
groups of non-steroidal estrogens that are widely distrib-
uted within the plant kingdom [35]. The phytoestrogen
genistein for example binds to ER with a preference for the
more recently described ER b [36]. In the present study,
Pygeum africanum extract displaced 3H-estradiol in a
competitive ligand-binding assay using mouse uterine
cytosol. This was in agreement with Mathe [21, 22] who
reported that Pygeum africanum had a phytoestrogenic
effect. Also, Pygeum africanum at the same concentration
displaced 3H-DHT in a competitive ligand-binding assay
using LNCaP cell cytosol. The androgen receptor binding
affinity of Pygeum africanum might help to explain the
inhibitory effect on 5 alpha reductase reported by Rhodes
et al. [23]. Recently some phytoestrogens (genistein and
daidzein) have been found to induce apoptosis and inhi-
bition of the PC-3 and LNCaP cell growth through their
binding and regulation of both ER and AR. Cao et al [37]
found that the expression of the ER-alpha and ER-beta
genes decreased, while AR gene was not expressed, after
incubation with genistein and daidzein in PC-3 cells. Also,
they reported that the apoptosis percentage of LNCaP cells
was elevated significantly by daidzein.
The effects of estrogens on prostate cancer have been
reviewed by Ho [38] and by Steiner and Raghow [39].
Estrogen therapy, principally the use of diethylstilbestrol
(DES), is a suggested practice in prostate tumor treatment.
Its primary mode of action is through feedback on the
anterior pituitary with suppression of gonadotropin secre-
tion and subsequent decrease in testosterone production by
Leydig cells of the testis. This in turn causes a decrease in
androgens required for hormone dependent cancer. How-
ever, direct effects of DES in the prostate are also possible.
Whether DES works directly in the prostate through a
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Fig. 3 PC-3 (A) and LNCaP (B) cells were plated at 1 · 104 cells per
well in 24 well dishes and grown to 50% confluence. After 2 days the
media was replaced with complete media containing 2.5 ll/ml of
Pygeum africanum (30% ethanol extract) and incubated for 72 h. The
total DNA concentration was determined at day 1, 2 and 3 by
thymidine incorporation assay. Values are means ± SEM of three
individual experiments (Each individual experiment was performed in
duplicate)
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classical ERa pathway, through ERb or another estrogen-
dependent mechanism has not been fully determined. The
present study showed a dose dependent inhibition of ERa
protein expression in PC-3 cells which express a significant
amount of ERa protein [2]. This was in agreement with
Mathe [21, 22] who reported that Pygeum africanum had
a phytoestrogenic effect on the prostate resulting in a sig-
nificant effect on the morphology of the glandular epithe-
lium of the mouse prostate presumably due to the effect of
weak anti-estrogens.
A recent review identified protein kinase C-a (PKC- a), a
serine–threonine kinase involved in cellular signaling path-
ways, as a target to modulate prostate cancer. PKC-a has
been found in both hormone insensitive (PC-3) and hormone
sensitive (LNCaP) prostate cancer cells [40]. The present
study found that Pygeum africanum at 2.5 ll/ml inhibited the
expression of PKC-a in LNCaP but not in PC-3 cells.
The present study showed that TRAMP mice fed Pyg-
eum africanum in a dose of 0.128 gm/kg of the diet showed
a significant and marked reduction of WDC tumor inci-
dence (35%) compared to mice fed casein diet (62.5%).
This could be explained by Pygeum africanum potentially
regulating prostate cancer in vivo through several mecha-
nisms including ERa, AR, PKC-a and apoptosis-related
mechanisms. The mice fed Pygeum africanum did not
show any significant difference from the mice fed casein in
Fig. 4 Cell cycle changes in
untreated PC-3 and LNCaP cells
(A & C) and PC-3 and LNCaP
cells treated with 2.5 ll/ml of
Pygeum africanum (B & D)
were detected by flow
cytometry. The untreated PC-3
and LNCaP cells showed
normal cell cycle events (A &
C) while the cells treated with
2.5 ll/ml of Pygeum africanum
showed accumulation of cells in
S phase of the cell cycle
(B & D). M1 ¼ G1 phase; M2
¼ S phase; M3 ¼ G2/M
phase
Table 1 Induction of apoptosis by the Pygeum africanum extract in
PC-3 and LNCaP cell lines as determined by the TUNEL assay
LNCaP (% apoptotic
events)
PC-3 (% apoptotic
events)
Negative control 0.94 ± 0.08a* 1.01 ± 0.10a
Positive control 22.90 ± 1.41b 20.75 ± 1.02b
Pygeum africanum 15.20 ± 1.19c 17.85 ± 0.86b
Mean ± SEM. Values are percent of total events counted. Values
within each column with different letter superscripts are significantly
different, P < 0.05 or less. N = 3 individual experiments and each
experiment was performed in duplicate. Negative control is the
untreated cells. Positive control is camphotechin treated cells 0
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Fig. 5 ER Saturation Binding Analysis—WT uterine cytosol was
incubated overnight at 4C with 3H-estradiol (5 nM final concentra-
tion) and the aliquot of Pygeum africanum (5ll/ml of 30% ethanol
extract) and B-sitosterol (5 lM). Bound and free ligands were
separated by dextran-coated charcoal and an aliquot of bound
radioactivity was measured by scintillation counting. Values are
means ± SEM of three individual experiments (Each individual
experiment was performed in duplicate). Bars designated with
asterisks are significantly different from no hormone, P < 0 05 or less
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terms of their total body weight, reproductive tract, testes
and prostate weights. This finding confirms the absence
of any obvious toxic effects among the mice fed Pygeum
africanum at this dose.
In conclusion, this study showed that Pygeum africanum
which is widely used in Europe and the USA for treatment
of BPH might be able to play a significant role in regulation
of prostate cancer both in vitro and in vivo. Thus, Pygeum
africanum may be of dual benefit to men who are at high
risk of developing either BPH or prostate cancer.
Materials and methods
Pygeum africanum bark was obtained from Nutraceutical
Corp./Solaray (Park City, UT) and was by weight 13%
total sterols. Ethanolic extracts (30% W/V) were made for
tissue culture experiments and stocks were kept at –20C.
Human reactive polyclonal antibody for ERa (PA1–308)
and PKC-a (PA1–405) were purchased from Affinity Bio
Reagents (Golden, CO). B-Sitosterol (98% pure) was ob-
tained from Sigma Chemical Co. (St. Louis, MO) and used
in tissue culture after being loaded on Cyclodextrin (CD)
vehicle to be accessible by the cultured cells [41]. Unla-
beled 17b estradiol and DHT were obtained from Sigma
Chemical Co. (St. Louis, MO). 3H-17b estradiol and 3H-
DHT were obtained from Amersham Pharmacia Biotech
(Piscataway, NJ).
In vitro experiments
Cell culture experiments
Human prostate carcinoma (PC3 and LNCaP) cells were
obtained from the ATCC and cultured in complete RPMI
1640 medium (Gibco Rockville, MD) supplemented with
10% fetal bovine serum (FBS), penicillin (100 units/ml)
streptomycin (100 lg/ml)), L-glutamine (5 mM)), NEAA
(0.1 mM Non Essential Amino Acids), HEPES buffer
(10 mM), glucose (2.5 gm/l) in 5% CO2 at 37C.
Growth inhibition curve and IC50: PC3 and LNCaP cells
were plated at 1 · 104 cells per well in 24 well dishes with
RPMI 1640 complete culture medium and cells were grown
to 50% confluence. After 2 days the media were replaced
with complete media with charcoal stripped serum [2] con-
taining 0–10 ll/ml of the Pygeum africanum extract or
0–25 lM of B-Sitosterol and incubated for 72 h. The media
were aspirated, cells washed twice with phosphate buffered
saline (PBS) (10 mM, pH 7.4), and 1N NaOH (250 ll)
added to lyse the cells. The total cellular protein concentra-
tion was determined by DC Bio-Rad assay using the manu-
facturer’s protocol (Bio-Rad laboratories, Hercules, CA).
The IC50 is the concentration where 50% of the maximum
Fig. 7 Western blot analysis of ERa protein expression in PC-3 cells
treated with different concentrations of Pygeum africanum using
human reactive polyclonal antibody. Extracts of PC-3 cell line were
resolved by gel electrophoresis, electro-blotted onto nitrocellulose
membrane, and immuno-detected as described in Materials and
Methods. Lane 1, 2 and 3 extracts of PC-3 cells treated with Pygeum
africanum (zero treatment control, 1 and 2.5 ll/ml of 30% ethanol
extract); lane 4, protein standard; lane 5, MCF-7 cells as a positive
control
Fig. 8 Western blot analysis of PKC-a protein expression in PC-3
and LNCaP cells treated with different concentrations of Pygeum
africanum using human reactive polyclonal antibody. Extracts of PC-
3 and LNCaP cell lines were resolved by gel electrophoresis, electro-
blotted onto nitrocellulose membrane, and immuno-detected as
described in Materials and Methods. (A) Lane 1, 2 and 3 extracts
of PC-3 cells treated with Pygeum africanum (zero treatment control,
1 and 2.5 ll/ml of 30% ethanol extract). (B) Lane 1, 2, and 3 extracts
of LNCaP cells treated with Pygeum africanum (zero treatment
control, 1 and 2.5 ll/ml of 30% ethanol extract)
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Fig. 6 AR Saturation Binding Analysis—LNCaP cell cytosol was
incubated overnight at 4C with 3H-DHT (5 nM final concentration)
and the aliquot of Pygeum africanum (5ll/ml of 30% ethanol extract)
and B-sitosterol (5 lM). Bound and free ligands were separated by
dextran-coated charcoal and an aliquot of bound radioactivity was
measured by scintillation counting. Values are means ± SEM of three
individual experiments (Each individual experiment was performed in
duplicate). Bars designated with asterisks are significantly different
from no hormone, P < 0 05 or less
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inhibition is observed. To calculate IC50, we first take the
difference between the protein value of the maximum inhi-
bition (where the growth curve levels out) and the protein
value of no inhibition at zero concentration. This difference
is multiplied by 0.5 and then the resulting protein value is
subtracted from the no inhibition protein value to obtain the
protein value that corresponds to the IC50 concentration of
the extract being used. 100% ethanol was used in the treat-
ment control group up to 1% final concentration without any
observed cell toxicity.
Time course study using thymidine incorporation assay:
PC3 and LNCaP cells were plated at 1 · 104 cells per well
in 24 well dishes with RPMI 1640 complete culture med-
ium and cells grown to 50% confluence. After 2 days the
media was replaced with complete media containing
2.5 ll/ml of Pygeum africanum extract and incubated for
24, 48 or 72 h. The cellular proliferation was determined
by thymidine incorporation assay [42].
Cell cycle kinetics: PC3 and LNCaP cells were plated
at 1 · 104 cells per well in 24 well dishes with RPMI 1640
complete culture medium and cells grown to 50%
confluence. After 2 days the media was replaced with
complete media containing 2.5 ll/ml of Pygeum africanum
extract and incubated for 72 h. The adherent cells were
released with trypsin, washed twice with phosphate buf-
fered saline (PBS) and collected by centrifugation. The cell
pellet was resuspended in 2.5 ml of cold ethanol (95%) for
1 h at 4C, washed with PBS, and incubated with 5 ll
RNase (20 lg/ml final concentration) at 37C for 30 min.
The cells were chilled on ice for 10 min then stained with
propidium iodide (50 lg/ml final concentration) for 1 h
and analyzed by flow cytometry (CyAn Flow, Cytomation,
Inc, Somerville, NJ).
Detection of apoptosis using TUNEL assay: PC3 and
LNCaP cells were plated at 1 · 106 cells in 100-mm cul-
ture dishes in RPMI 1640 complete media and grown to
50% confluence. After 2 days the media was replaced with
complete media containing 2.5 ll/ml of Pygeum africanum
extract and incubated for 72 h. The adherent cells were
released with trypsin, washed with PBS and processed for
labeling with fluorescein-tagged deoxyuridine triphosphate
nucleotide and propidium iodide by the use of an APO-
Direct Apoptosis Kit obtained from Phoenix Flow Systems
(San Diego, CA). The labeled cells were then analyzed by
flow cytometry.
Binding assays
3H-estradiol binding assay: Tissue cytosol preparation
(WT mouse uterine cytosol) and estradiol competition
binding analysis of Pygeum africanum extract were per-
formed as previously described [2].
3H-DHT binding assay: The capacity of pygeum afri-
canum extract to bind androgen receptor was assessed by
DHT competition binding assay using LNCaP cell cytosol
as previously described [43].
Western blotting for ER detection
Expression levels of both ERa and PKC-a in PC-3 and
LNCaP cells treated with IC50 of Pygeum africanum were
quantified by western immunoblot as previously described
[2]. We have controlled for the decrease in cell number
through cell cycle inhibition and apoptosis by loading the
same amount of protein in each lane (20 lg).
Table 2 Effect of Pygeum africanum on the incidence of prostate tumorigenesis in ERaWT/TRAMP mice
Diet n Phenotype
Non-cancer Cancer
Normal HYP PIN WDC MDC PDC
Casein 16 0 0 6(37.5%) 8(50%) 0 2(12.5%)
Pygeum africanuma 20 0 1(5%) 12(60%) 4(20%) 0 3(15%)
There was a statistically significant difference (P = 0.034) between the Pygeum africanum and casein diet regarding prostate tumorigenesis
Table 3 Body and organ weights of mice from different dietary groups
Weightsa (gm)
Diet Testes Body Repro. tract Prostate
Casein 0.19 ± 0.006 30.37 ± 0.45 1.55 ± 0.18 0.30 ± 0.18
Pygeum africanum 0.18 ± 0.008 29.46 ± 0.37 1.80 ± 0.47 0.40 ± 0.49
a Means ± SEM. No significant differences were seen between treatment groups
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In vivo experiments
Prostate cancer model
Animal protocols followed were approved by the Univer-
sity of Missouri Animal Care and Use Committee and
followed NRC guidelines. All breeder pairs were main-
tained on a casein-based diet (AIN 93G) as previously
described [44]. This model, known as TRAMP [45] for
TRansgenic Adenocarcinoma of the Mouse Prostate, was
developed by placing the SV40 early genes encoding T and
t antigens under the control of the rat probasin promoter,
which has been shown to be highly and specifically ex-
pressed in the mouse prostate [46]. The probasin (PB)
promoter is androgen and zinc regulated, with two andro-
gen response elements located in this region. PB is local-
ized in the ducts and nuclei of prostate epithelial cells, yet
PB’s function has not been identified. The transgene,
known as PBTag, is highly expressed in the dorsal and
ventral prostate lobes. This oncoprotein is known to abro-
gate tumor suppressor functions of p53 and Retinoblastoma
(Rb) and thereby drive the cell through the normal cell
cycle checkpoints. Mutations in p53 are important in the
prostate and occur in one third of early stage prostate
cancers [47, 48]. In our hands ~60–85% of TRAMP mice
develop prostate cancer spontaneously within 5 months.
The C57BL6/J TRAMP mice were housed in pairs in
breeder boxes with micro-isolator lids and given free ac-
cess to food and water. A daily light: dark cycle of 12:12 h
was used, with ambient temperature and humidity set at
21C, and 50%, respectively. Animals were monitored
weekly for body weight and tumor burden and were
euthanized after 5 months.
Dietary Pygeum africanum treatments
All breeder pairs were maintained on the casein-based diet
through pregnancy and lactation. At 6 weeks of age, male
TRAMP mice were randomly assigned to either the casein-
based diet (AIN 93G) or to the same diet to which Pygeum
africanum was added. The concentration of Pygeum afri-
canum was chosen in reference to the human consumption
dose in BPH [9, 10]. The mouse diet formulation contained
0.128 grams Pygeum africanum/kg diet, which was higher
than the recommended human dose in BPH but well within
the range attainable through supplements. The bark of
Pygeum Africanum was grounded and added as a dry
powder, the diet mixed in a Hobart mixer and pelleted
by dry, low heat extrusion into pellets. Animals were
given continual access to the diet and body weights were
recorded weekly.
At termination the reproductive tract (testes, vas defer-
ens, empty urinary bladder, seminal vesicles and prostate
lobes), testes and prostates were removed and weighed. At
the time of collection (5 months), a portion of each prostate
was fixed in neutral buffered formalin for histological
analysis and the remainder snap-frozen in liquid nitrogen
and stored at –80C.
Fig. 9 Stages of cancer in the TRAMP mouse prostate (H&E stained
sections, bar = 50 mm). (A) Normal prostate tubule (dorsal prostate)
with single epithelial layer and thin muscle wall. (B) Hyperplastic
prostate tubule with more numerous epithelial cells but retention of
simple layer and thin muscle wall. (C) Prostate tubule with prostate
intraepithelial neoplasia (PIN) and cribriform hyperplastic lesions and
thickened muscle wall. (D) Well-differentiated adenocarcinoma with
increased cribriform lesions, invasion of tubule wall and increased
mitotic rate in epithelium. (E) Moderately well-differentiated
adenocarcinoma with stratification or layering of epithelium and loss
of formation of tubules. (F) Poorly differentiated carcinoma with
‘‘neuroendocrine-like’’ pattern
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Tumor analysis
All lobes of the prostate glands were examined for nodular
expansion, excised, and weighed. If their appearance was
normal, then one dorsal lobe and all other lobes of the
prostate were snap-frozen in liquid nitrogen and subse-
quently stored at –80C. If nodules or abnormal findings
were observed in regions of the prostate other than the
dorsal lobe, the lesions were bisected, with half of the
sample fixed for histological evaluation and the other half
snap-frozen. The other dorsal prostate lobe and any
abnormal prostate lesions were immersed in 10% neutral
buffered formalin for 12–18 h, transferred to 70% ethanol
and then processed for paraffin embedment. Paraffin-
embedded tissues were cut in 4 micron sections and stained
with hematoxylin and eosin.
One or more sections of the dorsal prostate lobe were
assigned random numbers so as to blind the pathologist.
Prostate sections were examined and graded according to
morphologic criteria established for mouse models of
prostate cancer [49, 50]. The proliferative changes of the
secretory epithelia of the prostate tubules were recorded,
scored by independent veterinary pathologist who were
unaware of the treatment groups and assigned to one of the
following designations: (A) normal, (B) hyperplastic, (C)
prostatic intraepithelial neoplasia (PIN), (D) well-differ-
entiated carcinoma (WDC), (E) moderately well-differen-
tiated carcinoma (MDC), (F) poorly differentiated
carcinoma (PDC), invasive carcinoma with features
suggestive of neuroendocrine differentiation (Fig. 9) as
described previously [49, 50]. Proliferative and neoplastic
changes occur simultaneously throughout regions within
the prostate lobe(s) [49]. For example, a lobe of the dorsal
prostate may have several tubular sections with hyper-
plastic changes, and half the tubules with well-differenti-
ated adenocarcinoma. So the percentage of prostate
epithelium with hyperplastic or neoplastic changes is re-
corded, and a morphologic diagnosis is assigned to the
alteration observed in the greatest portion of the prostate
sample.
Statistical analysis
In vitro experiments
Data in Tables 1–3 were analyzed by one-way ANOVA
using the GLM procedure of SAS (Version 8, SAS
Institute Cary, NC). Post-hoc mean comparisons were
made using the Duncan’s Multiple Range component.
Means were considered significantly different at P < 0.05
or less. Data in Figs. 5 and 6 were analyzed by student t
test. Means were considered significantly different at
P < 0.05 or less.
In vivo experiments
Prostate histology was classified as non-cancer stages
(Normal, Hyperplasia and PIN) or cancer stages (WDC,
MDC, and PDC or neuro-endocrine like carcinoma). Tu-
mor incidence data was analyzed using X2 test. Values that
achieved P < 0.05 were considered to be significantly
different. Comparison within the same tumor stage be-
tween the two dietary groups has also been done. Body
weight, reproductive tract weight, testicular weight, and
prostate weight were analyzed using a two-sample t-test,
assuming unequal variance.
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